A. MENARINI PHARMA U.K. S.R.L.
Opportunity 68/100 (strong), bankability 70/100. High owner-dependency — earn-out structure likely required for clean transition. Share purchase looks the cleaner deal structure. Most likely exit: share sale to pe / searcher (65/100).
Data confidence
Overall: low (45/100)Sparse data coverage. Treat AI-generated outputs as preliminary. Manual diligence essential.
Solid opportunity signal. Worth a dedicated memo and management meeting.
Recent activity
Corporate timeline (33 events)Click to expand
- 2013-01-17📄dissolution-closure-of-uk-establishment-and-overseas-companydissolution · OSDS01
- 2013-01-17🏁Company dissolved
- 2012-08-30📄accounts-with-accounts-type-fullaccounts · AA
- 2011-08-19📄accounts-with-accounts-type-fullaccounts · AA
- 2010-07-13📄accounts-with-accounts-type-fullaccounts · AA
- 2009-10-22📄termination-person-authorised-overseas-companyofficers · OSTM03
- 2009-07-24📄accounts-with-accounts-type-fullaccounts · AA
- 2009-03-24📄accounts-with-accounts-type-fullaccounts · AA
- 2009-03-12📄legacyannual-return · BR4
- 2009-03-12📄legacyannual-return · BR4
- 2009-03-12📄legacyannual-return · BR4
- 2008-05-21➕MEI, Pio appointeddirector
- 2008-05-21➖LAFAURE, Christian resigneddirector
- 2007-12-02📄accounts-with-accounts-type-fullaccounts · AA
- 2007-01-11📄accounts-with-accounts-type-fullaccounts · AA
- 2006-08-08📄legacyannual-return · BR4
- 2006-08-08📄legacyannual-return · BR4
- 2006-08-08📄legacyannual-return · BR4
- 2006-08-08📄legacyannual-return · BR4
- 2006-05-23➕BERNOCCHI, Marco appointeddirector
- 2006-05-23➖FORESTI, Giorgio resigneddirector
- 2006-05-23➕LAFAURE, Christian appointeddirector
- 2006-05-23➖MASSELLI, Gianni resigneddirector
- 2005-01-06➕CRESCI, Giovanni appointeddirector
- 2005-01-06➕FORESTI, Giorgio appointeddirector
- 2005-01-06➕MASSELLI, Gianni appointeddirector
- 2005-01-06📄legacyincorporation · BR1-PAR
- 2005-01-06📄legacyincorporation · BR1-PAR
- 2005-01-06📄legacyincorporation · BR1-PAR
- 2005-01-06📄legacyincorporation · BR1-PAR
- 2005-01-06📄legacyincorporation · BR1-BCH
- 2005-01-06📄legacyincorporation · BR1
- 2004-12-20🏢Company incorporatedAs A. MENARINI PHARMA U.K. S.R.L.
Owner dependency
Material founder dependency. Consider a 2-3 year earn-out and build in a handover plan before completion.
- +Long-tenure founder: Senior director has been in place 21 years — deep operational knowledge concentrated in one person.
- +Founder age: Director aged approximately 80 — succession pressure is live.
Succession & seller-readiness
Strong acquirability signals converging. Worth approaching directly — this is how off-market deals start.
- primaryFounder aged 70+: Senior director is approximately 80 years old. Natural succession window is now.
- primary20+ year tenure: Director in role 21 years. Very long tenure is a classic succession signal.
- secondaryStable-but-static management: Company is 21 years old and no new directors in the last 3 years — succession not yet being planned internally.
- supportingClean filings + long tenure: Disciplined long-tenure operator — classic lifestyle-business pattern that often sells quietly.
Red flags
clean7 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Registered office
Filing status
Officers (0 active · 3 resigned)
Click a director name to see their full track record across all companies.